array(40) {
  [0]=>
  string(4) "8861"
  ["article_id"]=>
  string(4) "8861"
  [1]=>
  string(164) "CV Sciences, Inc. Receives Notice of Patent Allowance from USPTO for Proprietary Cannabidiol (CBD) and Nicotine Formulation for Treating Smokeless Tobacco Addiction"
  ["article_title"]=>
  string(164) "CV Sciences, Inc. Receives Notice of Patent Allowance from USPTO for Proprietary Cannabidiol (CBD) and Nicotine Formulation for Treating Smokeless Tobacco Addiction"
  [2]=>
  string(150) "Forthcoming Issuance of a U.S. Patent to Strengthen Drug Development Business Forthcoming Issuance of a U.S. Patent to Strengthen Drug Development Bus"
  ["short_description"]=>
  string(150) "Forthcoming Issuance of a U.S. Patent to Strengthen Drug Development Business Forthcoming Issuance of a U.S. Patent to Strengthen Drug Development Bus"
  [3]=>
  string(166) "Forthcoming Issuance of a U.S. Patent to Strengthen Drug Development Business 
Forthcoming Issuance of a U.S. Patent to Strengthen Drug Development Business
"
  ["description"]=>
  string(166) "Forthcoming Issuance of a U.S. Patent to Strengthen Drug Development Business 
Forthcoming Issuance of a U.S. Patent to Strengthen Drug Development Business
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "27"
  ["rss_id"]=>
  string(2) "27"
  [14]=>
  string(231) "http://www.globenewswire.com/news-release/2020/04/06/2012133/0/en/CV-Sciences-Inc-Receives-Notice-of-Patent-Allowance-from-USPTO-for-Proprietary-Cannabidiol-CBD-and-Nicotine-Formulation-for-Treating-Smokeless-Tobacco-Addiction.html"
  ["blog_url"]=>
  string(231) "http://www.globenewswire.com/news-release/2020/04/06/2012133/0/en/CV-Sciences-Inc-Receives-Notice-of-Patent-Allowance-from-USPTO-for-Proprietary-Cannabidiol-CBD-and-Nicotine-Formulation-for-Treating-Smokeless-Tobacco-Addiction.html"
  [15]=>
  string(19) "2020-04-06 20:45:00"
  ["add_date"]=>
  string(19) "2020-04-06 20:45:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-04-12 16:42:04"
  ["create_at"]=>
  string(19) "2020-04-12 16:42:04"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8862"
  ["article_id"]=>
  string(4) "8862"
  [1]=>
  string(51) "Silk Road Medical Provides COVID-19 Pandemic Update"
  ["article_title"]=>
  string(51) "Silk Road Medical Provides COVID-19 Pandemic Update"
  [2]=>
  string(150) "SUNNYVALE, Calif., April  06, 2020  (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and i"
  ["short_description"]=>
  string(150) "SUNNYVALE, Calif., April  06, 2020  (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and i"
  [3]=>
  string(276) "
SUNNYVALE, Calif., April  06, 2020  (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today provided a corporate update in response to the COVID-19 pandemic.
"
  ["description"]=>
  string(276) "
SUNNYVALE, Calif., April  06, 2020  (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today provided a corporate update in response to the COVID-19 pandemic.
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "27"
  ["rss_id"]=>
  string(2) "27"
  [14]=>
  string(122) "http://www.globenewswire.com/news-release/2020/04/06/2012078/0/en/Silk-Road-Medical-Provides-COVID-19-Pandemic-Update.html"
  ["blog_url"]=>
  string(122) "http://www.globenewswire.com/news-release/2020/04/06/2012078/0/en/Silk-Road-Medical-Provides-COVID-19-Pandemic-Update.html"
  [15]=>
  string(19) "2020-04-06 20:00:00"
  ["add_date"]=>
  string(19) "2020-04-06 20:00:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-04-12 16:42:04"
  ["create_at"]=>
  string(19) "2020-04-12 16:42:04"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8863"
  ["article_id"]=>
  string(4) "8863"
  [1]=>
  string(104) "OraSure Technologies Receives BARDA Contract for Rapid Oral Fluid Pan-SARS-Coronavirus In-home Self-test"
  ["article_title"]=>
  string(104) "OraSure Technologies Receives BARDA Contract for Rapid Oral Fluid Pan-SARS-Coronavirus In-home Self-test"
  [2]=>
  string(150) "BETHLEHEM, Pa., April  06, 2020  (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests, specimen c"
  ["short_description"]=>
  string(150) "BETHLEHEM, Pa., April  06, 2020  (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests, specimen c"
  [3]=>
  string(700) "
BETHLEHEM, Pa., April  06, 2020  (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests, specimen collection devices and microbiome laboratory and analytical services, today announced it has been awarded a $710,310 contract from the Biomedical Advanced Research and Development Authority (BARDA), part of the Department of Health and Human Services (HHS), to develop a pan-SARS-coronavirus antigen rapid in-home self-test that uses oral fluid samples.  This support from BARDA will enable OraSure to file for FDA Emergency Use Authorization (EUA) allowing for an in-home self-test to debut into the U.S. market.
"
  ["description"]=>
  string(700) "
BETHLEHEM, Pa., April  06, 2020  (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests, specimen collection devices and microbiome laboratory and analytical services, today announced it has been awarded a $710,310 contract from the Biomedical Advanced Research and Development Authority (BARDA), part of the Department of Health and Human Services (HHS), to develop a pan-SARS-coronavirus antigen rapid in-home self-test that uses oral fluid samples.  This support from BARDA will enable OraSure to file for FDA Emergency Use Authorization (EUA) allowing for an in-home self-test to debut into the U.S. market.
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "27"
  ["rss_id"]=>
  string(2) "27"
  [14]=>
  string(175) "http://www.globenewswire.com/news-release/2020/04/06/2011951/0/en/OraSure-Technologies-Receives-BARDA-Contract-for-Rapid-Oral-Fluid-Pan-SARS-Coronavirus-In-home-Self-test.html"
  ["blog_url"]=>
  string(175) "http://www.globenewswire.com/news-release/2020/04/06/2011951/0/en/OraSure-Technologies-Receives-BARDA-Contract-for-Rapid-Oral-Fluid-Pan-SARS-Coronavirus-In-home-Self-test.html"
  [15]=>
  string(19) "2020-04-06 18:00:00"
  ["add_date"]=>
  string(19) "2020-04-06 18:00:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-04-12 16:42:04"
  ["create_at"]=>
  string(19) "2020-04-12 16:42:04"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8951"
  ["article_id"]=>
  string(4) "8951"
  [1]=>
  string(84) "Medical device could 'revolutionise the patient experience of diabetes care'"
  ["article_title"]=>
  string(84) "Medical device could 'revolutionise the patient experience of diabetes care'"
  [2]=>
  string(71) "MPN editor Laura Hughes looks at the new diabetes technology in detail."
  ["short_description"]=>
  string(71) "MPN editor Laura Hughes looks at the new diabetes technology in detail."
  [3]=>
  string(71) "MPN editor Laura Hughes looks at the new diabetes technology in detail."
  ["description"]=>
  string(71) "MPN editor Laura Hughes looks at the new diabetes technology in detail."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "41"
  ["rss_id"]=>
  string(2) "41"
  [14]=>
  string(102) "https://www.medicalplasticsnews.com/news/could-this-technology-revolutionise-the-patient-experience-f/"
  ["blog_url"]=>
  string(102) "https://www.medicalplasticsnews.com/news/could-this-technology-revolutionise-the-patient-experience-f/"
  [15]=>
  string(19) "2020-04-06 17:30:15"
  ["add_date"]=>
  string(19) "2020-04-06 17:30:15"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-04-12 16:42:21"
  ["create_at"]=>
  string(19) "2020-04-12 16:42:21"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8801"
  ["article_id"]=>
  string(4) "8801"
  [1]=>
  string(66) "Bridging interventions best for hospital discharge of older adults"
  ["article_title"]=>
  string(66) "Bridging interventions best for hospital discharge of older adults"
  [2]=>
  string(150) "Interventions supporting medicines continuity in older people are most successful in preventing hospital readmission when they bridge the gap between "
  ["short_description"]=>
  string(150) "Interventions supporting medicines continuity in older people are most successful in preventing hospital readmission when they bridge the gap between "
  [3]=>
  string(188) "Interventions supporting medicines continuity in older people are most successful in preventing hospital readmission when they bridge the gap between hospital discharge and returning home."
  ["description"]=>
  string(188) "Interventions supporting medicines continuity in older people are most successful in preventing hospital readmission when they bridge the gap between hospital discharge and returning home."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "11"
  ["rss_id"]=>
  string(2) "11"
  [14]=>
  string(158) "https://www.pharmaceutical-journal.com/news-and-analysis/research-briefing/bridging-interventions-best-for-hospital-discharge-of-older-adults/20207870.article"
  ["blog_url"]=>
  string(158) "https://www.pharmaceutical-journal.com/news-and-analysis/research-briefing/bridging-interventions-best-for-hospital-discharge-of-older-adults/20207870.article"
  [15]=>
  string(19) "2020-04-06 17:27:00"
  ["add_date"]=>
  string(19) "2020-04-06 17:27:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-04-12 16:36:41"
  ["create_at"]=>
  string(19) "2020-04-12 16:36:41"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8952"
  ["article_id"]=>
  string(4) "8952"
  [1]=>
  string(69) "New technology offers better protection against cybersecurity threats"
  ["article_title"]=>
  string(69) "New technology offers better protection against cybersecurity threats"
  [2]=>
  string(140) "The new system launched by GE Healthcare, a manufacturer and distributor, aims to help hospitals monitor and mitigate cybersecurity threats."
  ["short_description"]=>
  string(140) "The new system launched by GE Healthcare, a manufacturer and distributor, aims to help hospitals monitor and mitigate cybersecurity threats."
  [3]=>
  string(140) "The new system launched by GE Healthcare, a manufacturer and distributor, aims to help hospitals monitor and mitigate cybersecurity threats."
  ["description"]=>
  string(140) "The new system launched by GE Healthcare, a manufacturer and distributor, aims to help hospitals monitor and mitigate cybersecurity threats."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "41"
  ["rss_id"]=>
  string(2) "41"
  [14]=>
  string(102) "https://www.medicalplasticsnews.com/news/new-technology-offers-better-protection-for-hospitals-agains/"
  ["blog_url"]=>
  string(102) "https://www.medicalplasticsnews.com/news/new-technology-offers-better-protection-for-hospitals-agains/"
  [15]=>
  string(19) "2020-04-06 17:13:50"
  ["add_date"]=>
  string(19) "2020-04-06 17:13:50"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-04-12 16:42:21"
  ["create_at"]=>
  string(19) "2020-04-12 16:42:21"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8953"
  ["article_id"]=>
  string(4) "8953"
  [1]=>
  string(58) "Company promises recyclable and reusable packaging by 2025"
  ["article_title"]=>
  string(58) "Company promises recyclable and reusable packaging by 2025"
  [2]=>
  string(150) "Global packaging company Amcor has partnered with the Healthcare Plastics Recycling Council (HPRC) in an attempt to ensure more sustainable practices "
  ["short_description"]=>
  string(150) "Global packaging company Amcor has partnered with the Healthcare Plastics Recycling Council (HPRC) in an attempt to ensure more sustainable practices "
  [3]=>
  string(196) "Global packaging company Amcor has partnered with the Healthcare Plastics Recycling Council (HPRC) in an attempt to ensure more sustainable practices and innovation across the healthcare industry."
  ["description"]=>
  string(196) "Global packaging company Amcor has partnered with the Healthcare Plastics Recycling Council (HPRC) in an attempt to ensure more sustainable practices and innovation across the healthcare industry."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "41"
  ["rss_id"]=>
  string(2) "41"
  [14]=>
  string(100) "https://www.medicalplasticsnews.com/news/company-promises-recyclable-and-reusable-packaging-by-2025/"
  ["blog_url"]=>
  string(100) "https://www.medicalplasticsnews.com/news/company-promises-recyclable-and-reusable-packaging-by-2025/"
  [15]=>
  string(19) "2020-04-06 17:03:38"
  ["add_date"]=>
  string(19) "2020-04-06 17:03:38"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-04-12 16:42:21"
  ["create_at"]=>
  string(19) "2020-04-12 16:42:21"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8864"
  ["article_id"]=>
  string(4) "8864"
  [1]=>
  string(81) "Coloplast A/S - Transactions in connection with share buy-back programme, week 14"
  ["article_title"]=>
  string(81) "Coloplast A/S - Transactions in connection with share buy-back programme, week 14"
  [2]=>
  string(123) "As mentioned in Announcement no. 02/2020 Coloplast is initiating a share buyback programme totalling up to DKK 500 million."
  ["short_description"]=>
  string(123) "As mentioned in Announcement no. 02/2020 Coloplast is initiating a share buyback programme totalling up to DKK 500 million."
  [3]=>
  string(134) "
As mentioned in Announcement no. 02/2020 Coloplast is initiating a share buyback programme totalling up to DKK 500 million.
"
  ["description"]=>
  string(134) "
As mentioned in Announcement no. 02/2020 Coloplast is initiating a share buyback programme totalling up to DKK 500 million.
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "27"
  ["rss_id"]=>
  string(2) "27"
  [14]=>
  string(149) "http://www.globenewswire.com/news-release/2020/04/06/2011883/0/en/Coloplast-A-S-Transactions-in-connection-with-share-buy-back-programme-week-14.html"
  ["blog_url"]=>
  string(149) "http://www.globenewswire.com/news-release/2020/04/06/2011883/0/en/Coloplast-A-S-Transactions-in-connection-with-share-buy-back-programme-week-14.html"
  [15]=>
  string(19) "2020-04-06 16:15:00"
  ["add_date"]=>
  string(19) "2020-04-06 16:15:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-04-12 16:42:04"
  ["create_at"]=>
  string(19) "2020-04-12 16:42:04"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8865"
  ["article_id"]=>
  string(4) "8865"
  [1]=>
  string(78) "Coloplast A/S - Transaktioner i henhold til aktietilbagekøbsprogram, uge 14"
  ["article_title"]=>
  string(78) "Coloplast A/S - Transaktioner i henhold til aktietilbagekøbsprogram, uge 14"
  [2]=>
  string(133) "Som meddelt i Selskabsmeddelelse nr. 02/2020 har Coloplast iværksat et tilbagekøbsprogram på i alt 500 millioner kroner. "
  ["short_description"]=>
  string(133) "Som meddelt i Selskabsmeddelelse nr. 02/2020 har Coloplast iværksat et tilbagekøbsprogram på i alt 500 millioner kroner. "
  [3]=>
  string(144) "
Som meddelt i Selskabsmeddelelse nr. 02/2020 har Coloplast iværksat et tilbagekøbsprogram på i alt 500 millioner kroner. 
"
  ["description"]=>
  string(144) "
Som meddelt i Selskabsmeddelelse nr. 02/2020 har Coloplast iværksat et tilbagekøbsprogram på i alt 500 millioner kroner. 
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "27"
  ["rss_id"]=>
  string(2) "27"
  [14]=>
  string(148) "http://www.globenewswire.com/news-release/2020/04/06/2011883/0/da/Coloplast-A-S-Transaktioner-i-henhold-til-aktietilbagek%C3%B8bsprogram-uge-14.html"
  ["blog_url"]=>
  string(148) "http://www.globenewswire.com/news-release/2020/04/06/2011883/0/da/Coloplast-A-S-Transaktioner-i-henhold-til-aktietilbagek%C3%B8bsprogram-uge-14.html"
  [15]=>
  string(19) "2020-04-06 16:15:00"
  ["add_date"]=>
  string(19) "2020-04-06 16:15:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-04-12 16:42:04"
  ["create_at"]=>
  string(19) "2020-04-12 16:42:04"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8814"
  ["article_id"]=>
  string(4) "8814"
  [1]=>
  string(60) "FDA Clears IND for Remestemcel Use in COVID-19 ARDS Patients"
  ["article_title"]=>
  string(60) "FDA Clears IND for Remestemcel Use in COVID-19 ARDS Patients"
  [2]=>
  string(150) "Melbourne, Australia; April 6, 2020; and New York, USA; April 5, 2020: Mesoblast Limited (ASX:MSB; Nasdaq: MESO), global leader in cellular medicines "
  ["short_description"]=>
  string(150) "Melbourne, Australia; April 6, 2020; and New York, USA; April 5, 2020: Mesoblast Limited (ASX:MSB; Nasdaq: MESO), global leader in cellular medicines "
  [3]=>
  string(249) "Melbourne, Australia; April 6, 2020; and New York, USA; April 5, 2020: Mesoblast Limited (ASX:MSB; Nasdaq: MESO), global leader in cellular medicines for inflammatory diseases, today announced that it has received clearance from the United States..."
  ["description"]=>
  string(249) "Melbourne, Australia; April 6, 2020; and New York, USA; April 5, 2020: Mesoblast Limited (ASX:MSB; Nasdaq: MESO), global leader in cellular medicines for inflammatory diseases, today announced that it has received clearance from the United States..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "15"
  ["rss_id"]=>
  string(2) "15"
  [14]=>
  string(202) "https://www.drugs.com/clinical_trials/fda-clears-ind-remestemcel-covid-19-ards-patients-18518.html?utm_source=ddc&utm_medium=rss&utm_campaign=FDA+Clears+IND+for+Remestemcel+Use+in+COVID-19+ARDS+Patients"
  ["blog_url"]=>
  string(202) "https://www.drugs.com/clinical_trials/fda-clears-ind-remestemcel-covid-19-ards-patients-18518.html?utm_source=ddc&utm_medium=rss&utm_campaign=FDA+Clears+IND+for+Remestemcel+Use+in+COVID-19+ARDS+Patients"
  [15]=>
  string(19) "2020-04-06 13:04:00"
  ["add_date"]=>
  string(19) "2020-04-06 13:04:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-04-12 16:36:45"
  ["create_at"]=>
  string(19) "2020-04-12 16:36:45"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8815"
  ["article_id"]=>
  string(4) "8815"
  [1]=>
  string(191) "First Two Patients Enrolled in Randomized Phase 2, COVID-19 Trial with Leronlimab; Five More Severely Ill COVID-19 Patients Treated Under Emergency IND and Two Patients Have Already Extubated"
  ["article_title"]=>
  string(191) "First Two Patients Enrolled in Randomized Phase 2, COVID-19 Trial with Leronlimab; Five More Severely Ill COVID-19 Patients Treated Under Emergency IND and Two Patients Have Already Extubated"
  [2]=>
  string(154) "VANCOUVER, Washington, April 06, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-sta"
  ["short_description"]=>
  string(154) "VANCOUVER, Washington, April 06, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-sta"
  [3]=>
  string(255) "VANCOUVER, Washington, April 06, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for..."
  ["description"]=>
  string(255) "VANCOUVER, Washington, April 06, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "15"
  ["rss_id"]=>
  string(2) "15"
  [14]=>
  string(300) "https://www.drugs.com/clinical_trials/first-two-patients-enrolled-randomized-phase-2-covid-19-trial-leronlimab-five-more-severely-ill-18510.html?utm_source=ddc&utm_medium=rss&utm_campaign=First+Two+Patients+Enrolled+in+Randomized+Phase+2%2C+COVID-19+Trial+with+Leronlimab%3B+Five+More+Severely+Ill+CO"
  ["blog_url"]=>
  string(300) "https://www.drugs.com/clinical_trials/first-two-patients-enrolled-randomized-phase-2-covid-19-trial-leronlimab-five-more-severely-ill-18510.html?utm_source=ddc&utm_medium=rss&utm_campaign=First+Two+Patients+Enrolled+in+Randomized+Phase+2%2C+COVID-19+Trial+with+Leronlimab%3B+Five+More+Severely+Ill+CO"
  [15]=>
  string(19) "2020-04-06 12:04:01"
  ["add_date"]=>
  string(19) "2020-04-06 12:04:01"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-04-12 16:36:45"
  ["create_at"]=>
  string(19) "2020-04-12 16:36:45"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8816"
  ["article_id"]=>
  string(4) "8816"
  [1]=>
  string(63) "INOVIO Initiates Phase 1 Clinical Trial Of Its COVID-19 Vaccine"
  ["article_title"]=>
  string(63) "INOVIO Initiates Phase 1 Clinical Trial Of Its COVID-19 Vaccine"
  [2]=>
  string(150) "PLYMOUTH MEETING, Pa., April 6, 2020 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (NASDAQ:INO) today announced that the U.S. Food and Drug Admini"
  ["short_description"]=>
  string(150) "PLYMOUTH MEETING, Pa., April 6, 2020 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (NASDAQ:INO) today announced that the U.S. Food and Drug Admini"
  [3]=>
  string(253) "PLYMOUTH MEETING, Pa., April 6, 2020 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (NASDAQ:INO) today announced that the U.S. Food and Drug Administration has accepted the company's Investigational New Drug (IND) application for INO-4800, its..."
  ["description"]=>
  string(253) "PLYMOUTH MEETING, Pa., April 6, 2020 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (NASDAQ:INO) today announced that the U.S. Food and Drug Administration has accepted the company's Investigational New Drug (IND) application for INO-4800, its..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "15"
  ["rss_id"]=>
  string(2) "15"
  [14]=>
  string(212) "https://www.drugs.com/clinical_trials/inovio-initiates-phase-1-clinical-trial-covid-19-vaccine-18509.html?utm_source=ddc&utm_medium=rss&utm_campaign=INOVIO+Initiates+Phase+1+Clinical+Trial+Of+Its+COVID-19+Vaccine"
  ["blog_url"]=>
  string(212) "https://www.drugs.com/clinical_trials/inovio-initiates-phase-1-clinical-trial-covid-19-vaccine-18509.html?utm_source=ddc&utm_medium=rss&utm_campaign=INOVIO+Initiates+Phase+1+Clinical+Trial+Of+Its+COVID-19+Vaccine"
  [15]=>
  string(19) "2020-04-06 11:04:43"
  ["add_date"]=>
  string(19) "2020-04-06 11:04:43"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-04-12 16:36:45"
  ["create_at"]=>
  string(19) "2020-04-12 16:36:45"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}